Calidi Biotherapeutics (CLDI) Preferred Shares Issued (2023)
Calidi Biotherapeutics' quarterly Preferred Shares Issued came in at $14.7 million in Q3 2023, up 8780.12% quarter-over-quarter from $166000.0 in Q2 2023.
Calidi Biotherapeutics has reported Preferred Shares Issued for 1 years, with the latest figure at $14.7 million in Q3 2023.
- For the quarter ending Q3 2023, Preferred Shares Issued changed N/A year-over-year to $14.7 million; the trailing twelve-month figure through Dec 2023 stood at $14.9 million (changed N/A YoY), and the FY2023 full-year result was $14.9 million, up 7544.62% from the prior year.
- Preferred Shares Issued for Q3 2023 stood at $14.7 million, up from $166000.0 in the prior quarter.
- The five-year high for Preferred Shares Issued was $14.7 million in Q3 2023, with the low at $166000.0 in Q2 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Shares Issued (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,638,563.89 Bn | 1,638,563.89 Bn | - | - |
| 2 | Alterity Therapeutics | 767,934.24 Bn | 767,934.20 Bn | - | - |
| 3 | Legend Biotech | 2,937.00 Bn | 2,936.10 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,282.79 Bn | 2,282.72 Bn | - | - |
| 5 | Akari Therapeutics | 2,169.69 Bn | 2,169.69 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 110.41 Bn | 103.16 Bn | 2.59 Bn | - |
| 7 | Regeneron Pharmaceuticals | 66.44 Bn | 57.69 Bn | 3.31 Bn | - |
| 8 | Evaxion A | 65.44 Bn | 65.42 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.53 Bn | 36.52 Bn | 959.66 Mn | - |
| 10 | Calidi Biotherapeutics | - | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | 14.74 Mn |
| Sep 30, 2023 | 14.74 Mn |
| Jun 30, 2023 | 166,000.00 |
| Jun 30, 2023 | 166,000.00 |